Division of Clovis Oncology Inc.
Latest From EOS SPA
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.
The oncology drug developer expects to file its third generation EGFR inhibitor for the treatment of NSCLC by the end of 2015, CEO Patrick Mahaffy told investors during an R&D day Jan. 27. Investors are enthusiastic about the potential of the drug, which could address a sizeable commercial market.
In its latest deal, Eddingpharm continues its march forward from a third-party promotional partner for companies like GSK, to a China-based specialty pharma. After in-licensing a string of compounds last year, it has now added three more from ACT Biotech.
- Therapeutic Areas
- Ethical Oncology Science
- Western Europe
- Parent & Subsidiaries
- Clovis Oncology Inc.
- Senior Management
Silvano Spinelli, CEO
Gabriella Camboni, COO
- Contact Info
Phone: (39) 2 87391608
Via Monte di Pieta n.1/A
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.